Author/Editor     Karrer, K; Micksche, M; Pridun, N; Theuer, W; Ulsperger, E; Orel, J; Eržen, J; Hrabar, B; Klevišar, M; Debevec, M; Rott, T
Title     Surgery in SCLC as first step of multimodality treatment
Type     članek
Source     Anticancer Res
Vol. and No.     Letnik 14
Publication year     1994
Volume     str. 327-31
Language     eng
Abstract     186 patients received surgery for cure followed by agressive randomized chemotherapy and PCI. After a median follow-up time of about 60 months the observed 4-year overall survival rate for patients completely resected was: 58% for 68 patients with pT1-3NoMo, and 33% for 27 patients with pT1-3 pN2Mo stages of SCLC. These promising results have to be confirmed by larger cooperative studies to support the recommendation to initiate surgery without delay, i.e. without preoperative chemotherapy for SCLC as well as for the non-SCLCs. From 148 patients in ISC study III after preoperative (neoadjuvant) schemotherapy only 12 received surgery for pT1-3N2Mo but only one of them survived 36 months and none 48 months p.o.
Descriptors     LUNG NEOPLASMS
CARCINOMA, SMALL CELL
SURVIVAL RATE
NEOPLASM STAGING
FOLLOW-UP STUDIES
MULTICENTER STUDIES
CYCLOPHOSPHAMIDE
DOXORUBICIN
LOMUSTINE
VINCRISTINE
METHOTREXATE
IFOSFAMIDE
MESNA